The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Abstract
Genetic evidence suggests that inhibition of amyloid fibril formation by small molecules should be effective against amyloid diseases. Known amyloid inhibitors appear to function by shifting the aggregation equilibrium away from the amyloid state. Here, we describe a series of transthyretin amyloidosis inhibitors that functioned by increasing the kinetic barrier associated with misfolding, preventing amyloidogenesis by stabilizing the native state. The trans-suppressor mutation, threonine 119 → methionine 119, which is known to ameliorate familial amyloid disease, also functioned through kinetic stabilization, implying that this small-molecule strategy should be effective in treating amyloid diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
Protein misfolding, evolution and disease
Dobson, C. M. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01445-0 · Cited by 1,952
Amyloid pores from pathogenic mutations
Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., & Lansbury, P. T. (2002) · Nature · doi:10.1038/418291a · Cited by 1,289
Protein aggregation: folding aggregates, inclusion bodies and amyloid
Fink, A. L. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00002-9 · Cited by 1,157
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Alzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875
Alternative conformations of amyloidogenic proteins govern their behavior
Kelly, J. W. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80089-3 · Cited by 593
Self-citationIs there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease?
Goldberg, M. S., & Lansbury Jr, P. T. (2000) · Nature Cell Biology · doi:10.1038/35017124 · Cited by 458
Rational design of potent human transthyretin amyloid disease inhibitors.
Sacchettini, J. C., Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., & Kelly, J. W. (2000) · Nature Structural Biology · doi:10.1038/74082 · Cited by 379
Self-citationSequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Self-citationInhibiting transthyretin amyloid fibril formation via protein stabilization
Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15051 · Cited by 344
Self-citationTrans -Suppression of Misfolding in an Amyloid Disease
Hammarström, P., Schneider, F., & Kelly, J. W. (2001) · Science · doi:10.1126/science.1062245 · Cited by 293
Self-citationConversion of PrP to a Self-Perpetuating PrP Sc -like Conformation in the Cytosol
Ma, J., & Lindquist, S. (2002) · Science · doi:10.1126/science.1073619 · Cited by 287
A protein-folding reaction under kinetic control
Baker, D., Sohl, J. L., & Agard, D. A. (1992) · Nature · doi:10.1038/356263a0 · Cited by 280
Therapeutic strategies for human amyloid diseases
Sacchettini, J. C., & Kelly, J. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd769 · Cited by 261
Self-citationAn Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denatured
Jiang, X., Smith, C. S., Petrassi, H. M., Hammarström, P., White, J. T., Sacchettini, J. C., & Kelly, J. W. (2001) · Biochemistry · doi:10.1021/bi011194d · Cited by 239
Self-citationInhibiting transthyretin conformational changes that lead to amyloid fibril formation
Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., & Kelly, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.12956 · Cited by 206
Self-citationComparison of Lethal and Nonlethal Transthyretin Variants and Their Relationship to Amyloid Disease
McCutchen, S. L., Lai, Z., Miroy, G. J., Kelly, J. W., & Colon, W. (1995) · Biochemistry · doi:10.1021/bi00041a032 · Cited by 198
Self-citationJiang, X., Buxbaum, J. N., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261419998 · Cited by 166
Self-citationOza, V. B., Smith, C., Raman, P., Koepf, E. K., Lashuel, H. A., Petrassi, H. M., Chiang, K. P., Powers, E. T., Sachettinni, J., & Kelly, J. W. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010257n · Cited by 133
Self-citationEvaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma
Purkey, H. E., Dorrell, M. I., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091431798 · Cited by 124
Self-citationSignificance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogs
Schloss, J. V. (1988) · Accounts of Chemical Research · doi:10.1021/ar00153a005 · Cited by 110
Genetic Aspects of Amyloidosis
Jacobson, D. R., & Buxbaum, J. N. (1991) · Springer eBooks · doi:10.1007/978-1-4684-5958-6_2 · Cited by 82
Hammarström, P., Jiang, X., Deechongkit, S., et al. (2001) · Biochemistry · doi:10.1021/bi010673+ · Cited by 75
Hypokalemic periodic paralysis mutations: Confirmation of mutation and analysis of founder effect
Grosson, C. L. S., Esteban‐Pérez, J., McKenna-Yasek, D. M., Gusella, J. F., & Brown, R. H. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(95)00018-6 · Cited by 47
Cited by
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
Self-citationStefani, M., & Dobson, C. M. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0464-5 · Cited by 1,651
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Self-citationRationalization of the effects of mutations on peptide andprotein aggregation rates
Chiti, F., Stefani, M., Taddei, N., Ramponi, G., & Dobson, C. M. (2003) · Nature · doi:10.1038/nature01891 · Cited by 1,072
Conformational constraints for amyloid fibrillation: the importance of being unfolded
Uversky, V. N., & Fink, A. L. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.12.008 · Cited by 1,015
Metadata
- Authors
- Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W.
- Venue
- Science
- Published
- 2003-01-31
- Volume
- 299
- Issue
- 5607
- Pages
- 713-716
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1972373816
- Cited by
- 525
- References
- 26
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.